PTGDR2: Prostaglandin D2 receptor 2
Receptor for prostaglandin D2 (PGD2).
- Drugs that act on it: 16
- Approved: 1
- In phases 1 to 3: 15
- Sponsors: 10
Who is on it, and how far along
Every drug ChEMBL records acting on PTGDR2, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 13
- Other 3
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Novartis Pharmaceuticals213%
- Amgen16%
- AstraZeneca Pharmaceuticals16%
- Boehringer Ingelheim Pharmaceuticals16%
- Chiesi Farmaceutici16%
- Idorsia Pharmaceuticals Ltd.16%
- KARE Biosciences16%
- Merck & Co. (MSD)16%
- Pfizer16%
- Pulmagen Therapeutics16%
| Ramatroban | Approved | KARE Biosciences | Small molecule | Antagonist | 0 |
| Fevipiprant | Phase 3 | Novartis Pharmaceuticals | Small molecule | Antagonist | 0 |
| Setipiprant | Phase 3 | Idorsia Pharmaceuticals Ltd. | Small molecule | Antagonist | 0 |
| Timapiprant | Phase 3 | Chiesi Farmaceutici | Small molecule | Antagonist | 0 |
| ADC3680 | Phase 2 | Pulmagen Therapeutics | Other | Antagonist | 0 |
| ARRY-502 | Phase 2 | Pfizer | Small molecule | Antagonist | 0 |
| AZD1981 | Phase 2 | AstraZeneca Pharmaceuticals | Small molecule | Antagonist | 0 |
| BI-671800 | Phase 2 | Boehringer Ingelheim Pharmaceuticals | Small molecule | Antagonist | 0 |
| Donitriptan | Phase 2 | — | Small molecule | Antagonist | 0 |
| MK-1029 | Phase 2 | Merck & Co. (MSD) | Other | Antagonist | 0 |
| QAV680 | Phase 2 | Novartis Pharmaceuticals | Small molecule | Antagonist | 0 |
| Vidupiprant | Phase 2 | Amgen | Small molecule | Antagonist | 0 |
| AM-211 | Phase 1 | — | Small molecule | Antagonist | 0 |
| AM-461 | Phase 1 | — | Small molecule | Antagonist | 0 |
| MK-7246 | Phase 1 | — | Small molecule | Antagonist | 0 |
| RG7185 | Phase 1 | — | Other | Antagonist | 0 |
- Asthma0.43
- Seasonal allergic rhinitis0.29
- Nasal polyposis0.28
- Atopic asthma0.21
- COVID-190.19
- Neurodegenerative disease0.19
- Perennial allergic rhinitis0.18
- Allergic rhinitis0.12
- Chronic obstructive pulmonary disease0.11
- Allergic asthma0.11
- Atopic eczema0.10
- Acute myeloid leukemia0.10
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5071, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt Q9Y5Y4, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets